- Editorial: only steps away from primetime? Hepatitis B virus RNA as a routine marker to guide HBV treatment decisions-authors' replyXia, Muye; Chi, Heng; Janssen, Harry L. A.; Peng, Jie*Alimentary Pharmacology and Therapeutics, 2021, 54(7): 972-973.
- LONGER-TERM EXPERIENCE WITH TENOFOVIR ALAFENAMIDE (TAF) IN HBV-INFECTED PATIENTS; CHANGES IN EGFR, FIB4, ALT, AND DNA SUPPRESSIONReddy, K Rajender; Curry, Michael P; Bae, Ho S; Dieterich, Douglas T; Ankoma Sey, Victor; Pan, Calvin Q; Hann, Hie Won L; Tong, Myron J; Kim, W Ray; Kwo, Paul Yien; Frazier, Lynn; Cox, Kimmi; Milligan, Scott; Afdhal, Nezam HAnnual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, 2019-11-08 To 2019-11-12.
- Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosisDeng, Rui; Wang, Ziyan; Liu, Yuxin; Sun, Jian*Hepatology, 2023.
期刊论文
Editorial: the three tenors in HBV-TDF, TAF and now TMF. Authors' reply
11阅读
